A multicentre study suggested that the high density of CD180 in marginal zone lymphoma (MZL) can be used in a test panel as a marker to distinguish MZL from other lymphomas and leukemias with similar characteristics (Mayeur-Rousse et al. 2016). Here, CD180 is linked to lymphoma.